MAPT and Parkinson disease: Genetic and pharmacological inhibition of NLRP3 in various mouse models shows protection against Aβ plaque formation, Tau hyperphosphorylation, rotenone-induced PD, and related cognitive declines, highlighting NLRP3’s potential as a therapeutic target (Heneka et al., 2013; Dempsey et al., 2017; Martinez et al., 2017; Ising et al., 2019).